Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
15.73
-0.23 (-1.44%)
Aug 7, 2025, 4:00 PM - Market closed
Company Description
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease.
The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 362 |
| CEO | Eric Venker |
Contact Details
Address: 320 West 37th Street, 6th Floor New York, New York 10018 United States | |
| Phone | 917 580 3099 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | Chief Executive Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Michael Geffner M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Tiago M. Girao CPA | Chief Financial Officer |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
| Lauren Schrier M.B.A. | Vice President of Marketing |
| Christine Blodgett | Senior Vice President of Human Resources |
| Andy Deig | Senior Vice President of Strategic Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 29, 2025 | 8-K | Current Report |
| Jul 9, 2025 | ARS | Filing |
| Jul 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 9, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 25, 2025 | 144 | Filing |
| Jun 13, 2025 | 144 | Filing |
| Jun 3, 2025 | 144 | Filing |
| May 29, 2025 | 10-K | Annual Report |
| May 29, 2025 | 8-K | Current Report |
| May 21, 2025 | 144 | Filing |